Company Description
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in t...
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Valuation
Price to Sales Ratio
52.52
Price to Book Ratio
6.84
Enterprise Value to EBITDA
-43.49
Enterprise Value to Sales
211.46
Total Debt to Enterprise Value
0.02
Efficiency
Revenue/Employee
185,878.00
Income Per Employee
-430,228.00
Receivables Turnover
17.18
Total Asset Turnover
0.11
Liquidity
Current Ratio
9.59
Quick Ratio
9.59
Cash Ratio
9.34
Profitability
Operating Margin
-235.51
Pretax Margin
-231.46
Net Margin
-231.46
Return on Assets
-26.56
Return on Equity
-33.69
Return on Total Capital
-31.96
Return on Invested Capital
-31.84
Capital Structure
Total Debt to Total Equity
7.46
Total Debt to Total Capital
6.94
Total Debt to Total Assets
5.81
Long-Term Debt to Equity
6.38
Long-Term Debt to Total Capital
5.93
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. John M. Leonard | 62 | 2014 | Director & Chief Medical Officer |
| Mr. Glenn Goddard | 48 | 2018 | Executive VP, Chief Financial & Accounting Officer |
| Dr. Laura Sepp-Lorenzino | 60 | 2019 | Chief Scientific Officer & Executive VP |
| Dr. Eliana Clark | - | - | Senior Vice President-Technical Operations |
| Dr. David Lebwohl | - | 2020 | Chief Medical Officer & Executive Vice President |
Insider Actions
| 01/03/2022 |
Derek Hicks EVP, Chief Business Officer |
19,118 | Award at $0 per share. | 0 |
| 11/05/2021 |
David Lebwohl EVP, Chief Medical Officer |
200 | Disposition at $135.34 per share. | 27,068 |
| 11/05/2021 |
David Lebwohl EVP, Chief Medical Officer |
548 | Disposition at $134.07 per share. | 73,470 |
| 11/05/2021 |
David Lebwohl EVP, Chief Medical Officer |
452 | Disposition at $132.62 per share. | 59,944 |
| 11/05/2021 |
David Lebwohl EVP, Chief Medical Officer |
1,200 | Disposition at $131.71 per share. | 158,052 |
| 11/05/2021 |
David Lebwohl EVP, Chief Medical Officer |
2,400 | Derivative/Non-derivative trans. at $12.62 per share. | 30,288 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
250 | Disposition at $130.47 per share. | 32,617 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
525 | Disposition at $129.83 per share. | 68,160 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
225 | Disposition at $129.01 per share. | 29,027 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
849 | Disposition at $127.81 per share. | 108,510 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
551 | Disposition at $126.92 per share. | 69,932 |
| 10/14/2021 |
David Lebwohl EVP, Chief Medical Officer |
2,400 | Derivative/Non-derivative trans. at $12.62 per share. | 30,288 |
| 10/11/2021 |
John Francis Crowley Director |
2,500 | Disposition at $119.55 per share. | 298,875 |
| 10/11/2021 |
John Francis Crowley Director |
2,500 | Derivative/Non-derivative trans. at $18.83 per share. | 47,075 |
| 10/05/2021 |
John Francis Crowley Director |
200 | Disposition at $132.84 per share. | 26,568 |
| 10/05/2021 |
John Francis Crowley Director |
1,846 | Disposition at $131.74 per share. | 243,192 |
| 10/05/2021 |
John Francis Crowley Director |
3,759 | Disposition at $130.92 per share. | 492,128 |
| 10/05/2021 |
John Francis Crowley Director |
2,915 | Disposition at $129.88 per share. | 378,600 |
| 10/05/2021 |
John Francis Crowley Director |
1,280 | Disposition at $128.83 per share. | 164,902 |
| 10/05/2021 |
John Francis Crowley Director |
10,000 | Derivative/Non-derivative trans. at $18.83 per share. | 188,300 |
| 09/24/2021 |
David Lebwohl EVP, Chief Medical Officer |
7,923 | Derivative/Non-derivative trans. at $12.62 per share. | 99,988 |
| 09/21/2021 |
David Lebwohl EVP, Chief Medical Officer |
2,400 | Disposition at $149.81 per share. | 359,544 |
| 09/21/2021 |
David Lebwohl EVP, Chief Medical Officer |
2,400 | Derivative/Non-derivative trans. at $12.62 per share. | 30,288 |
| 09/07/2021 |
Glenn Goddard EVP, Chief Financial Officer |
3,482 | Disposition at $180.12 per share. | 627,177 |
| 09/07/2021 |
Glenn Goddard EVP, Chief Financial Officer |
3,482 | Derivative/Non-derivative trans. at $14.58 per share. | 50,767 |
| 09/01/2021 |
John M. Leonard President and CEO; Director |
44,735 | Disposition at $170 per share. | 7,604,950 |
| 09/01/2021 |
John M. Leonard President and CEO; Director |
15,985 | Derivative/Non-derivative trans. at $18.3 per share. | 292,525 |
| 09/01/2021 |
John M. Leonard President and CEO; Director |
28,750 | Derivative/Non-derivative trans. at $23.46 per share. | 674,475 |
| 08/31/2021 |
John M. Leonard President and CEO; Director |
37,833 | Disposition at $155 per share. | 5,864,115 |
| 08/31/2021 |
Glenn Goddard EVP, Chief Financial Officer |
24,800 | Disposition at $160.22 per share. | 3,973,456 |
| 08/31/2021 |
John M. Leonard President and CEO; Director |
37,833 | Derivative/Non-derivative trans. at $14.58 per share. | 551,605 |
| 08/31/2021 |
Glenn Goddard EVP, Chief Financial Officer |
1,817 | Derivative/Non-derivative trans. at $14.58 per share. | 26,491 |
| 08/31/2021 |
Glenn Goddard EVP, Chief Financial Officer |
22,983 | Derivative/Non-derivative trans. at $19.27 per share. | 442,882 |
MarketWatch News on NTLA
-
Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
- Barron's Online
-
Beam Gets FDA Nod for First Gene-Editing Trial
- Barron's Online
-
Prime Is the Newest Gene Editing, and It's Getting Better
- Barron's Online
-
This Fund Is Winning Big by Betting on Stocks That Help Humanity
- Barron's Online
-
Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI
- Tomi Kilgore
-
The Best and Worst Biopharma Stock Performers So Far in 2021
- Barron's Online
-
Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform
- Tonya Garcia
-
Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy
- Tonya Garcia
-
Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough
- Barron's Online
-
First In-Vivo Gene Editing Data Look Good for Intellia
- Barron's Online
-
Biotech M&A Has Been Slow This Year. Why It Might Get Busier.
- Barron's Online
-
Biotech stocks are a buy — especially these 18 picks
- Michael Brush
-
With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge
- Barron's Online
-
Intellia Therapeutics price target raised to $106 from $39 at Raymond James
- Tonya Garcia
- Loading more headlines...
Other News on NTLA
-
It's Time To Go To Cash For The Next 7 Years - 1-Year Update
- Seeking Alpha
-
5 Charts to Remember if the Stock Market Crashes in 2022
- Motley Fool
-
11 Good And 4 Bad Reasons To Keep Holding ARK Invest
- Seeking Alpha
-
Is Beam Therapeutics a Good Stock to Buy Now?
- Motley Fool
-
"Motley Fool Money" 2022 Investing Preview
- Motley Fool
-
Genomic Medicine 2021: (Happy To) Turn The Page
- Seeking Alpha
-
3 Healthcare Stocks That Could Rocket Higher in 2022
- Motley Fool
-
Better Buy: CRISPR vs. Intellia
- Motley Fool
- Loading more headlines...
